Biosimilars production in Africa opportunities & challenges.
Regul Toxicol Pharmacol
; 149: 105626, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38636774
ABSTRACT
The healthcare systems of African nations heavily rely on importing and repackaging biological medicine. More than 70% of the pharmaceutical products consumed in Africa are imported. The localization of biosimilar production can have a positive impact on the availability and cost of these products by reducing the expenses for African governments and making essential healthcare products more accessible to the population. However, it is evident that the developing countries, particularly African nations, face various obstacles and difficulties in localizing biosimilar production. These challenges encompass development, manufacturing, evaluation, and registration processes. In this review, we will highlight the significant hurdles and achievements encountered during the localization process of biosimilars.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Medicamentos Biossimilares
País como assunto:
Africa
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article